AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02424188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRIIUMPH Intervention
Description: Group and individual smoking cessation and weight management counseling, pharmacotherapy with varenicline or bupropion and nicotine replacement therapy, group exercise, and text messaging support
Study NCT00551265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00551265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00551265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00551265 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oregovomab
Description: Given IV
Study NCT00551265 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oregovomab
Description: Given IV
Study NCT01280162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin piperaquine
Description: 40/320 mg tablets, 9 tablets total
Study NCT00558259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate 150 mg twice daily (BID)
Description: dabigatran etexilate capsules 150 mg BID
Study NCT00558259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo twice daily (BID)
Description: Matching placebo BID
Study NCT02443090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fispemifene
Study NCT02443090 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01315587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (Magstim rapid2 )
Description: * 3 pulses at 50Hz repeated each 200 ms for 2 seconds~* 80% MT~* 20 days treatment
Study NCT04102098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
Study NCT04102098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Study NCT00573508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Administration
Study NCT00573508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate
Description: Oral Administration
Study NCT04091555 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: HLNatural Tension
Description: Understand the impact of the supplement on Tension Headaches
Study NCT03969212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: IPs less than 12 years old will receive either 2 mg/kg (if weight less than 20 kg) or 40 mg (if weight more than or equal to 20 kg) of Baloxavir Marboxil as oral suspension. IPs more than or equal to 12 years old will receive either 40 mg (if weight less than 80 kg) or 80 mg (if weight more than or equal to 80 kg) of Baloxavir Marboxil as tablets. HHCs of IPs will not receive study medication.
Study NCT03969212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IPs less than 12 years old will receive placebo oral suspension and those above 12 years will receive placebo tablets. HHCs of IPs will not receive study medication.
Study NCT02628990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1.6 g plant stanols
Description: Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols
Study NCT02628990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 g plant stanols
Description: Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols
Study NCT02628990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1.6 g plant stanols and camelina oil
Description: Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols and camelina oil
Study NCT02628990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 g plant stanols and camelina oil
Description: Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols and camelina oil
Study NCT02628990 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lipid-lowering effect of Placebo Yoghurt Drink
Study NCT01720108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban and ASA
Study NCT01720108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban and ASA
Study NCT01315587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (Magstim rapid2)
Description: LDLPFC 110% MT 15 Hz 20 days
Study NCT01315587 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation(Magstim rapid2)
Description: Placebo treatment: Sham coil
Study NCT00964093 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Silver Alginate
Description: (Algidex ™)
Study NCT02072161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: ETC-1002 capsules, taken once daily oral
Study NCT02072161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, taken once daily oral
Study NCT02072161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin Therapy
Description: Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.
Study NCT02072161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statin Therapy
Description: Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.
Study NCT01148914 — intervention group
Intervention type: OTHER
Intervention: Inflammatory biomarkers
Description: tTst blood samples for cardiac biomarkers at baseline, 24-hours and 3 month post-ablation
Study NCT00514891 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: The effect of vitamin A given with different vaccines will be studied
Study NCT00514891 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Description: The effect of vitamin A given with different vaccines will be studied
Study NCT02634489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin HCl
Description: Oral
Study NCT02634489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate
Description: Oral
Study NCT02634489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC905
Description: Oral
Study NCT03276325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-nalbuphine
Description: Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
Study NCT03276325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone-nalbuphine
Description: Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
Study NCT01873820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium ascorbate
Study NCT01873820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Study NCT04643522 — intervention group
Intervention type: OTHER
Intervention: Clinical assessment
Description: Comparison of semen analysis results and sex-related hormone levels between the dependent groups which were defined as before COVID-19 and after COVID-19 (the data of the same patient group were compared as before and after the diagnosis of COVID-19).
Study NCT04223427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Directional and single ring STN-DBS on gait
Description: Surgery for STN-DBS and STN-LFP recordings during gait initiation (M1): 15 days~* Surgery for STN-DBS electrodes implantation~  * Placement of stimulation electrodes according to the usual procedure, including a MRI with contrast product~ * Intraoperative electrophysiological recordings~ * Intraoperative clinical evaluation~ * Intraoperative identification of the electrodes and final position with X-Ray~ * Post-operative 3D helical TDM without iode injection~* STN-LFP recordings during gait initiation performed 3 to 5 days after surgery~* Placement of the neurostimulator (5 days after surgery)~* Acute testing of STN-DBS for first parameters setting programming~Follow-up of the patient with outpatient visits as usually performed in PD patients operated for STN-DBS with progressive adaptation of parameters settings using single-ring stimulation.~Directional and single ring STN-DBS on gait (M7)
Study NCT04223427 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Directional and single ring STN-DBS on gait
Description: Surgery for STN-DBS and STN-LFP recordings during gait initiation (M1): 15 days~* Surgery for STN-DBS electrodes implantation~  * Placement of stimulation electrodes according to the usual procedure, including a MRI with contrast product~ * Intraoperative electrophysiological recordings~ * Intraoperative clinical evaluation~ * Intraoperative identification of the electrodes and final position with X-Ray~ * Post-operative 3D helical TDM without iode injection~* STN-LFP recordings during gait initiation performed 3 to 5 days after surgery~* Placement of the neurostimulator (5 days after surgery)~* Acute testing of STN-DBS for first parameters setting programming~Follow-up of the patient with outpatient visits as usually performed in PD patients operated for STN-DBS with progressive adaptation of parameters settings using single-ring stimulation.~Directional and single ring STN-DBS on gait (M7)
Study NCT01711723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darapladib 160 mg
Description: Subjects in each group received one tablet orally of Darapladib 160 mg daily for 10 consecutive days. Tablets were taken with food, swallowed whole, not chewed.
Study NCT00975767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD265+erlotinib
Description: MGCD265 and erlotinib administered daily
Study NCT00975767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD265+docetaxel
Description: MGCD265 administered daily; docetaxel administered once every 3 weeks
Study NCT00545051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po monthly for 12 months
Study NCT00545051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate
Description: 150mg po monthly for 12 months
Study NCT00557934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dobutamine
Description: dobutamine stress (10 µg/kg/min) for 10 minutes during heart catheterization
Study NCT00799513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
Study NCT01234753 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Physician and nurse consultation
Description: Usual care by a visit to physician at the hospital out-patient clinic and computer-based and individual education and psychosocial support by a nurse-led session.
Study NCT00728611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRGF
Description: intra auricular injection 6mg
Study NCT00728611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid
Description: 20 mg / 2 ml
Study NCT00728611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: physiological water 3cc + lidocain 3cc
Study NCT03972254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Interaction Guidance
Description: The main steps in the procedure are to have the family identify the primary concern they are facing, highlight the strengths that the family already has in place and expand on those strengths, convey/impart caregiving and societal norms, and offer other perspectives (McDonough, 2004). The goal of this therapy is to engage the family to take an active role in the construction of their overall treatment. The individualized treatment approach focuses and builds on existing strengths.
Study NCT03690232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucose water
Description: 3 sessions of 6cc 25% glucose injection with a 2-week interval
Study NCT03690232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic aicd
Description: intra-articular HA ((Hyruan Plus® , average MW 3000 kD; LG Life Sciences Ltd, Korea)) for sessions with a 1-week interval between each treatment
Study NCT01248065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
Study NCT01248065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Description: Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)
Study NCT01248065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciclesonide
Description: Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)
Study NCT00893984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
Study NCT04331145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 60mg
Description: Platelet reactivity will be assessed by VerifyNow P2Y12 assay in ALL enrolled patients after confirmed use of clopidogrel for 4 days prior TAVI. Patients that have not completed a pre-treatment period of 4 days of clopidogrel will receive a loading dose of 300mg, according to the clinical practice, with assessment of platelet reactivity by VerifyNow P2Y12 at the following 6 hours. Based on results of basal VerifyNow P2Y12 assay at least 24 hours before the index-TAVI procedure, patients with:~High on-treatment platelet reactivity (PRU ≥ 160 assessed with VerifyNow P2Y12 assay): Patients will be switched to receive ticagrelor 60mg twice daily initiating at least 24hrs before TAVI procedure, in order to arrive to the index TAVI procedure with at least two doses of 60 mg, and will continue with Ticagrelor 60mg twice per day during the following three months.
Study NCT02487732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 90mg twice daily for 5 weeks
Study NCT02487732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Prasugrel 10mg once daily for 5 weeks
Study NCT03720873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib or gefitinib or icotinib
Description: Patients will be treated with erlotinib 150mgQD or gefitinib250mgQD or icotinib 125 mg TID
Study NCT03720873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Patients will be treated with Anlotinib 12mg po d1-14 Q21d
Study NCT03312283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lucentis
Description: intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
Study NCT03312283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1205
Description: intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
Study NCT01383499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium bromide
Description: inhalation solution administered via Respimat in 3 different doses
Study NCT01383499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide
Description: inhalation solution administered via Respimat in 3 different doses
Study NCT00003849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00616057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synergy 1
Description: 8 grams/day during the first week and then 8 grams twice a day during 3 months
Study NCT00616057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: 8 grams/day during the first week and then 8 grams twice a day during 3 months
Study NCT02572882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: p-inulin
Description: 12 week self-administered treatment phase
Study NCT03700073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group (GTVR)
Description: Gait training with a robotic system (CL1Walker) combined with immersion in a Virtual Reality program
Study NCT03700073 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group (GT)
Description: Gait training with a robotic system (CL1Walker) alone.
Study NCT01847469 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced-Cognitive Processing Therapy-C (E-CPT-C)
Study NCT01847469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced-Cognitive Processing Therapy-C (E-CPT-C)
Study NCT01847469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Study NCT01847469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01877473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Study NCT01452321 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex
Study NCT01452321 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex
Study NCT04447846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Initiation of treatment will begin with 5 mg/kg/day given in two divided doses. The dose will be increased by 5 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 20 mg/kg/day given.
Study NCT03932669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: 150-300mg daily dose of nilotinib
Study NCT04345120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-008
Description: The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.
Study NCT03781999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Actiful
Description: supplement containing 500 mg orange extract and 200 mg pomegranate actives
Study NCT03781999 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study NCT04016467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic manipulation
Description: High velocity, small amplitude thrust treatment to spine that elicits a neurophysiologic response.
Study NCT04016467 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham thoracic treatment
Description: Hand placement on thorax without thrust.
Study NCT01942265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: Subjects will receive two doses of the A/H7N9 vaccine with or without AS03 delivered intramuscularly 21 days apart.
Study NCT01942265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59
Description: Subjects will receive two doses of the A/H7N9 vaccine with or without MF59 delivered intramuscularly 21 days apart.
Study NCT01942265 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Description: Subjects will receive two doses of the A/H7N9 vaccine with or without an adjuvant delivered intramuscularly approximately 21 days apart.
Study NCT01795573 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cultured Treg cells
Description: Co-culturing of recipient dendritic cells and donor Treg. Treg administration will occur 2 days before the allogeneic stem cell transplant (i.e. day -2 with reference of day 0 as stem cell infusion date).
Study NCT00819520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Description: Two single doses of oral ivermectin 400 mcg/kg (Days 1 and 8) plus 2 single applications of placebo lotion
Study NCT00819520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: malathion
Description: Two single applications of malathion 0.5% lotion (Days 1 and 8) plus 2 single doses of placebo tablets